Patient-centric design for systemic peptide delivery: Trends in routes of administration and advancement in drug delivery technologies
Manuel Sanchez-Felix
Senior Fellow, Novartis
Utilizing peptides as therapeutic agents is considered an attractive approach for the treatment of various diseases due to their high binding and selectivity to novel drug targets. However, the physicochemical properties of peptides make them challenging to administer exogenously, which places a high burden on drug delivery technology selection to achieve the desired response successfully. Various peptide drug delivery systems have been used in clinical and marketed products to overcome the problems associated with the exogenous administration of peptide therapeutics. This review details the trends observed pertaining to the delivery of peptides such as changes in the routes of administration, advancements in formulation platforms, patient-centric product design, and various other aspects of peptide delivery.
Dr. Manuel Sanchez-Felix is a Senior Fellow with the Chemical and Pharmaceutical Profiling (CPP) group at the Novartis Institutes for BioMedical Research in Cambridge, MA. He is a scientific leader with over 20 years of experience in drug discovery and development where he co-invented and contributed to the successful development and launch of various pharmaceutical products.
At Novartis, Dr. Sanchez-Felix leads a cross-functional group from Discovery and Development that is responsible for the evaluation and implementation of external Novel Delivery Technologies. His previous position at Novartis involved heading a group of scientists at the interface between Research and Development, establishing physicochemical and biopharmaceutical properties, and combining this information to initiate development strategy and formulation design. Prior to joining Novartis, Manuel was at Eli Lilly & Company for 20 years. His area of expertise includes Biopharmaceutics, drug delivery and patient-centered formulation design. Areas of drug discovery where he has developed products include CNS, infectious diseases (specifically TB, Malaria and Rheumatic fever), oncology, bone regeneration, and diabetes.
Dr. Sanchez-Felix received his B.Sc. Honors degree and Ph.D in Chemistry from the University of Surrey, UK. He is also an Adjunct Professor in the Department of Industrial and Physical Pharmacy at Purdue University (West Lafayette, IN) and a Fellow of the Royal Society of Chemistry. Recently, he has joined the Advisory Board of both the Biomedical Programs at Middlesex Community College and Northeastern University who have a program supporting students from minority communities.